Loading company…
Neurona Therapeutics is a clinical-stage biotherapeutics company developing cell therapies for chronic neurological disorders.
Based in San Francisco, US, and founded in 2008 by co-founder and CEO Cory R. Nicholas, Neurona develops cell-based therapeutics for neurological diseases. Its lead candidate, NRTX-1001, is made of inhibitory GABAergic interneurons derived from pluripotent stem cells and is being studied for drug-resistant mesial temporal lobe epilepsy. In April 2025 the company raised USD 102 million in venture funding from investors including Fidelity Investments, Ysios Capital Partners, and Viking Global Investors, plus other investors. Its listed stage is Series F.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in